Clinical trials: Rectal Adenocarcinoma
Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
This phase II/III trial compares the effect of usual treatment approach alone (FOLFOX or CAPOX after chemoradiation) with using FOLFIRINOX after chemoradiation in patients with stage II-III rectal cancer.
- Conditions
- Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Locally Advanced Rectal Adenocarcinoma
- Trial name
- JANUS (NCT05610163)
- Testing
- Capecitabine, 5-fluorouracil, Leucovorin calcium
- Where
- 685 sites in United States, Puerto Rico
- Volunteers
- 760 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06128551
- Testing
- Elironrasib, Daraxonrasib
- Where
- 56 sites in United States, France and 5 more
- Volunteers
- 534 people
- Sponsor
- Revolution Medicines, Inc.
Locally Advanced Rectal Adenocarcinoma
Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer
The goal of this clinical trial is to learn whether new adjuvant radiotherapy with gross tumor volume(GTV) escalated to 58.75 Gy can improve complete response (CR) rates compared with GTV dose of 50 Gy in adult patients (18-79…
- Trial name
- SIB-NCRT (NCT07200141)
- Testing
- GTV 58.75 Gy/25 fractions(Simultaneous Integrated Boost), GTV 50 Gy/25 fractions(Simultaneous Integrated Boost), Concurrent Chemotherapy
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Peking Union Medical College Hospital
Advanced Solid Tumor, Non-Small Cell Lung Cancer
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or…
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07629960
- Testing
- BLU-924
- Where
- 16 sites in United States, Spain
- Volunteers
- 265 people
- Sponsor
- Blueprint Medicines Corporation
Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma
Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer
This study looks at the level of circulating tumor elements (cancer cells or DNA pieces floating in the blood) and how it may be related to how the tumor responds to standard treatment in patients with rectal cancer that has…
- Conditions
- Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Rectosigmoid Adenocarcinoma, Recurrent Rectal Adenocarcinoma
- Trial name
- NCT02874885
- Testing
- Biospecimen Collection
- Where
- United States
- Volunteers
- 341 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Quality of Life (QOL), Mismatch Repair Deficient Colorectal Cancer
Research on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI Tumors
This cohort study is divided into two parts: Part A: Registry Cohort All patients with non-metastatic, MMRd/MSI-H colorectal cancers (and other gastrointestinal cancers for exploratory analysis) who have signed the general…
- Conditions
- Quality of Life (QOL), Mismatch Repair Deficient Colorectal Cancer, Microsatellite Instability-High Colorectal Cancer, Stage II Colorectal Cancer
- Trial name
- RESIST (NCT07829081)
- Testing
- Active surveillance after complete response to immunotherapy in MMRd GI cancers, Stand of Care
- Where
- 3 sites in Switzerland
- Volunteers
- 234 people
- Sponsor
- University Hospital, Basel, Switzerland
Rectal Cancer, Adenocarcinoma of Rectum
ABCSG R07 Rectal Cancer Registry
In Austria, patients with rectal cancer that has not spread to other parts of the body are typically treated with either total neoadjuvant therapy (TNT) or immunotherapy, depending on their microsatellite status (DNA repair…
- Trial name
- ABCSG R07 RCR (NCT07780305)
- Where
- 3 sites in Austria
- Volunteers
- 600 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8
Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
This study measures the levels of circulating tumor DNA (ctDNA) in patients with stage II-III rectal cancer before, during, and after treatment to find out if the presence or absence of ctDNA in patient's blood using the…
- Conditions
- Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8
- Trial name
- NCT05081024
- Testing
- Biopsy, Biospecimen Collection, Electronic Health Record Review
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- OHSU Knight Cancer Institute
Bladder Carcinoma, Ureter Carcinoma
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors.
- Conditions
- Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
- Trial name
- ORACLE (NCT05059444)
- Testing
- Guardant Reveal
- Where
- 57 sites in United States, France and 3 more
- Volunteers
- 2,285 people
- Sponsor
- Guardant Health, Inc.
Rectal Cancer, Adenocarcinoma
HDR Endorectal Brachytherapy With 3D-Printed Guidance and Local Shielding for Rectal Cancer Organ Preservation
This prospective, single-center, single-arm phase II study will evaluate the efficacy, safety, and technical feasibility of an organ-preserving radiotherapy strategy for patients with localized rectal adenocarcinoma who are…
- Trial name
- NOM-HDR-W (NCT07786493)
- Testing
- High-Dose-Rate Endorectal Brachytherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Rectal Adenocarcinoma
Neoadjuvant Radiotherapy vs Upfront Surgery in Locally Advanced Proximal Rectal Cancer
The PRELUDE Study: A Prospective Cohort Study Comparing Neoadjuvant Radiotherapy Followed by Total Mesorectal Excision Versus Upfront Surgery in Patients with Locally Advanced Proximal Rectal Cancer The PRELUDE Study is a…
- Trial name
- PRELUDE (NCT07802197)
- Testing
- radiotherapy, surgery
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Istanbul University
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
This trial examines colorectal cancer incidence in participants with 1 to 2 non-advanced adenomas randomized to surveillance colonoscopy at 10 years compared to participants randomized to surveillance colonoscopy at 5 and 10…
- Trial name
- FORTE (NCT05080673)
- Testing
- 5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy
- Where
- 493 sites in United States, Puerto Rico
- Volunteers
- 9,500 people
- Sponsor
- NRG Oncology
Metastatic Colon Adenocarcinoma, Metastatic Colon Cancer
xDRIVE in Metastatic Colorectal Cancer
The study aims to evaluate the clinical utility of the xDRIVE functional precision medicine + artificial intelligence (AI) platform in predicting treatment response for metastatic colorectal cancer (mCRC).
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colon Cancer, Metastatic Rectal Adenocarcinoma, Metastatic Rectal Carcinoma
- Trial name
- NCT06929338
- Testing
- Functional precision medicine
- Sponsor
- First Ascent Biomedical Inc.
Rectal Adenocarcinoma, Rectal Cancer
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
Rectal cancer patients who do not achieve a complete response to standard of care chemotherapy and radiation often require surgical resection as part of curative intent therapy.
- Trial name
- NCT07292298
- Testing
- High Rare Dose Rectal Brachytherapy Boost
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- University of Colorado, Denver
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
This phase I/II trial tests the safety, side effects, best dose, and efficacy of FOLFOX and bevacizumab in combination with botensilimab and balstilimab (3B-FOLFOX) in treating patients with microsatellite stable (MSS) colorectal…
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma
- Trial name
- NCT05627635
- Testing
- Balstilimab, Bevacizumab, Biospecimen Collection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Rectal Adenocarcinoma, Stage I Rectal Cancer AJCC v8
Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer
This study evaluates quality of life and utilities following surgical treatment of stage I-IV rectal cancer. This study may help researches learn more about quality of life in patients who have or have had rectal cancer.
- Conditions
- Rectal Adenocarcinoma, Stage I Rectal Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8
- Trial name
- NCT02107105
- Testing
- Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 430 people
- Sponsor
- M.D. Anderson Cancer Center
Bowel Cancer, Polyp Rectal
Use of a Novel Camera to Check the Bowel After Polyp or Tumour Removal
1.1 Polyps or tumours in the lower part of the bowel (rectum) can be removed using instruments inserted through the bottom which avoids major surgery and the possibility of a stoma bag (colostomy).
- Conditions
- Bowel Cancer, Polyp Rectal, Rectal Cancer, Rectal Adenocarcinoma
- Trial name
- R-ALERT (NCT07341126)
- Testing
- LumenEye X1 digital rectoscope
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Edinburgh
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma
Understanding New Cachexia Subtypes Through Observational Epidemiological Research
The UNCOVER study is a longitudinal observational cohort focused on patients at high risk for cancer cachexia. At Kaiser Permanente Northern California, up to 800 individuals with advanced or unresectable non-small cell lung…
- Conditions
- Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
- Trial name
- UNCOVER (NCT07776353)
- Testing
- Biospecimen Collection, Computed Tomography, Electronic health record review
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- Kaiser Permanente
Rectal Adenocarcinoma, High-Risk Cancer
NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC
To explore the efficacy and safety of adding a ketogenic diet and/or high-dose intravenous vitamin C to neoadjuvant short-course radiotherapy followed by mFOLFOX6 chemotherapy combined with serplulimab in patients with locally…
- Conditions
- Rectal Adenocarcinoma, High-Risk Cancer, MSS
- Trial name
- CRI-KEV (NCT07765667)
- Testing
- Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer
This phase 1b trial studies the side effects and best dose of TAS-102 when given together with radiation therapy in treating patients with stage II-III rectal cancer that has not been treated and can be removed by surgery…
- Conditions
- Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
- Trial name
- NCT04104139
- Testing
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Trifluridine and Tipiracil Hydrochloride
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- OHSU Knight Cancer Institute